New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
08:55 EDTNVS, NVS, NVS, PG, PG, PGFDA to hold a public hearing
The FDA holds a public hearing on the Over-the-Counter Drug Monograph System at FDA Silver Spring, Maryland offices on March 25-26 at 9 am. Webcast Link
News For NVS;PG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
07:02 EDTPGProcter & Gamble reports Q1 core EPS $1.07, consensus $1.07
Subscribe for More Information
October 23, 2014
15:44 EDTPGProcter & Gamble October weekly 83 straddle priced for 2% move into Q1
Subscribe for More Information
15:39 EDTPGNotable companies reporting before tomorrow's open
Subscribe for More Information
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
06:25 EDTPGLuxottica announces arrival of co-CEO for Markets Adil Mehboob-Khan
Subscribe for More Information
06:13 EDTPGProcter & Gamble narrows potential CEO successors to four, WSJ reports
Subscribe for More Information
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
18:14 EDTPGProcter & Gamble narrows pool of potential CEO candidates, WSJ says
Subscribe for More Information
14:20 EDTPGProcter & Gamble October weekly volatility increases into Q1 and outlook
Subscribe for More Information
12:09 EDTPGLuxottica to name P&G executive as co-CEO, Bloomberg says
Eyeglass maker Luxottica (LUX), which is in the midst of a boardroom upheaval, will name Procter & Gamble (PG) executive Adil Mehboob-Khan as a co-CEO, says Bloomberg, citing people familiar with the matter. Reference Link
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
October 21, 2014
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
October 17, 2014
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
October 16, 2014
15:10 EDTPGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
October 15, 2014
17:03 EDTNVSNovartis announces CTL019 data demonstrating efficacy in certain ALL patients
Novartis and the University of Pennsylvania's Perelman School of Medicine announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine, or NEJM, evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia, or r/r ALL. The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor, or CAR, therapy CTL019. Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA. Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%.
October 14, 2014
11:23 EDTNVSBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
10:08 EDTPGProcter & Gamble: There is no doubt we are in a stretch of global volatility
The company said there is a high amount of volatility both politically and economically. The company said it is "trying its best" and that they're "on it."
09:26 EDTPGProcter & Gamble sees significant savings opportunities
The company plans to create a new P&G over the next 18-24 months that will consist of 70-80 brands organized in a dozen businesses. The company plans to reduce waste, and to have a North Aerican supply chain redesign that will see fewer, multi-category plants and more common manufacturing platforms. Comments taken from P&G Annual Meeting of Shareholders.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use